Anne Barman Caldwell
Yale University · 28 works · 4,663 citations · h-index 14
Top works
- Nivolumab plus Ipilimumab in Advanced Melanoma
- The 5-Year Experience of Modified Fat Diets on Younger Men with Coronary Heart Disease
- The Energy Expenditure of 9- to 11-Year-old Boys and Girls (1) Standing Drawing and (2) Dressing and Undressing
- The Energy Expenditure of Boys and Girls 9 to 11 Years of Age (1) Sitting Listening to the Radio (Phonograph), (2) Sitting Singing, and (3) Standing Singing
- Nutrition Survey and Tests in Bataan, Philippines
- Studies on Cooking Fats and Oils
- Weight Reduction and Serum Cholesterol Levels
- Proteins of the turkey erythrocyte membrane
- Triiodothyronine Stimulation of Cyclic Adenosine 3’, 5’-Monophosphate Accumulation in Fat Cells*
- Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL).
- Immune regulation of canine tumour and macrophage PD‐L1 expression
- The effects of two low fat dietary patterns on the blood cholesterol level of young male coronary patients
- Inhibition by Cycloheximide and Dactinomycin of the Activation of Lipolysis Due to Growth Hormone in White Fat Cells
- PD ‐1 expression by canine T cells and functional effects of PD ‐1 blockade
- Bodily Storage of Vitamin A in Relation to Diet and Age Studied by Means of the Antimony Trichloride Reaction Using a Photoelectric Colorimeter
- Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy
- A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents
- Test for the Determination of Starch in Meat Food Products (Applicable for Estimation of Cereal in Sausages)
- Minimal Toxicity Seen When Pembrolizumab Is Added to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: Early Results from an Ongoing Phase II Trial (ECOG-ACRIN EA9171)
- Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)